{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:04:33Z","timestamp":1792145073994,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.cell.2015.08.015","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T20:20:39Z","timestamp":1441311639000},"page":"1257-1270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1079,"title":["Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity"],"prefix":"10.1016","volume":"162","author":[{"given":"Santiago","family":"Zelenay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarthe\u00a0G.","family":"van\u00a0der\u00a0Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan\u00a0P.","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn\u00a0J.","family":"Snelgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie\u00a0E.","family":"Acton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Probir","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u00a0Romina","family":"Girotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio\u00a0A.","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caetano","family":"Reis\u00a0e\u00a0Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2015.08.015_bib1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2015.08.015_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","article-title":"Smoldering and polarized inflammation in the initiation and promotion of malignant disease","volume":"7","author":"Balkwill","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CMR.0b013e32831d7f52","article-title":"COX-2 expression in malignant melanoma: a novel prognostic marker?","volume":"19","author":"Becker","year":"2009","journal-title":"Melanoma Res."},{"key":"10.1016\/j.cell.2015.08.015_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T\u00a0cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2164-15-190","article-title":"Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma","volume":"15","author":"Castle","year":"2014","journal-title":"BMC Genomics"},{"key":"10.1016\/j.cell.2015.08.015_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.3831","article-title":"Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection","volume":"21","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2015.08.015_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.immuni.2014.02.013","article-title":"Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages","volume":"40","author":"Coulombe","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2015.08.015_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.08.015_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00310-6","article-title":"Targeting cyclooxygenase-2 in human neoplasia: rationale and promise","volume":"4","author":"Dannenberg","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib10","first-page":"303","article-title":"Expression of cyclooxygenase 2 in human malignant melanoma","volume":"61","author":"Denkert","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.cell.2015.08.015_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","article-title":"Oncogenic Braf induces melanocyte senescence and melanoma in mice","volume":"15","author":"Dhomen","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib12","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.cell.2015.08.015_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2015.08.015_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature10803","article-title":"Expression of tumour-specific antigens underlies cancer immunoediting","volume":"482","author":"DuPage","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.08.015_bib15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2015.08.015_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2015.08.015_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nbt.3101","article-title":"Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases","volume":"33","author":"Frock","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2015.08.015_bib18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T\u00a0cell responses through CD8alpha+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.cell.2015.08.015_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e3181eacbd8","article-title":"Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy","volume":"16","author":"Gajewski","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.cell.2015.08.015_bib20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2015.08.015_bib21","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cncr.27817","article-title":"Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women\u2019s Health Initiative","volume":"119","author":"Gamba","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cell.2015.08.015_bib22","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr2089","article-title":"Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study","volume":"10","author":"Gierach","year":"2008","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cell.2015.08.015_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4161\/cbt.2.6.627","article-title":"Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression","volume":"2","author":"Goulet","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cell.2015.08.015_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib26","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","article-title":"GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells","volume":"42","author":"Helft","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2015.08.015_bib27","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T\u00a0cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.08.015_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.08.015_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.cell.2015.08.015_bib30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI66236","article-title":"Host immunity contributes to the anti-melanoma activity of BRAF inhibitors","volume":"123","author":"Knight","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2015.08.015_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.cmr.0000194430.77643.a0","article-title":"Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression","volume":"16","author":"Ku\u017abicki","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.cell.2015.08.015_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.08.015_bib33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.08.015_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.08.015_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cell.2015.08.015_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-12-0464","article-title":"Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes","volume":"3","author":"Pedersen","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cell.2015.08.015_bib37","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1073\/pnas.1303302110","article-title":"Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment","volume":"110","author":"Phan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2015.08.015_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrc2541","article-title":"Toll-like receptors and cancer","volume":"9","author":"Rakoff-Nahoum","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2015.08.015_bib39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cell.2015.08.015_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib41","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2015.08.015_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T\u00a0cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cell.2015.08.015_bib43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.08.015_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cell.2015.08.015_bib45","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1158\/1078-0432.CCR-05-0683","article-title":"Novel genes associated with malignant melanoma but not benign melanocytic lesions","volume":"11","author":"Talantov","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cell.2015.08.015_bib46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CEJ.0b013e328339648c","article-title":"Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer","volume":"19","author":"Tian","year":"2010","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.cell.2015.08.015_bib47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cell.2015.08.015_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cell.2015.08.015_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1309\/4EJ9KL7CGDENVVLE","article-title":"Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions","volume":"124","author":"Wenzel","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.cell.2015.08.015_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature03954","article-title":"Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance","volume":"437","author":"Willimsky","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cell.2015.08.015_bib51","doi-asserted-by":"crossref","first-page":"242ra84","DOI":"10.1126\/scitranslmed.3008455","article-title":"COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models","volume":"6","author":"Xu","year":"2014","journal-title":"Sci. Transl. Med."}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867415010284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867415010284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T14:59:35Z","timestamp":1537369175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867415010284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0092867415010284"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2015.08.015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725773108.793510804","asserted-by":"object"}]},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2015.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}